Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Blood Cells, Molecules & Diseases|January 27, 2007
Design of antisense oligonucleotides and short interfering RNA duplexes (siRNA) targeted to BCL6 mRNA: towards rational drug development for specific lymphoma subsetsAnna Kalota, J B OpalinskaBlood|November 3, 2009
A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cellsAnna Kalota, Alan M GewirtzCancer Biology & Therapy|January 17, 2004
Progress in the development of nucleic acid therapeutics for cancerAnna Kalota, Susan E Shetzline, Alan M GewirtzAnticancer Research|March 14, 2007
Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude miceIntae Lee, Anna Kalota, Alan M Gewirtz, et al.Blood|September 27, 2008
The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cellsHuiwu Zhao, Anna Kalota, Shenghao Jin, et al.Cancer Cell|September 13, 2011
Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemiaGerd A Blobel, Anna Kalota, Patricia V Sanchez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2013
Intrinsic resistance to JAK2 inhibition in myelofibrosisAnna Kalota, Grace R Jeschke, Martin Carroll, et al.Plos One|April 28, 2015
Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survivalAnna Kalota, Mary A Selak, Laura A Garcia-Cid, et al.Nature Medicine|October 27, 2004
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cellsAndrzej Ptasznik, Yuji Nakata, Anna Kalota, et al.Annals of the New York Academy of Sciences|December 6, 2006
Nucleic acid therapeutics for hematologic malignancies--theoretical considerationsJoanna B Opalinska, Anna Kalota, Jyoti Chattopadhyaya, et al.Pageof 3